Prof. Wenhua Xiao 肖文华
Chief Physician, Professor
Department of Medical Oncology, Chinese PLA General Hospital (301 Hospital), First Medical Center, Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Standardized chemotherapy, autologous and allogeneic hematopoietic stem cell transplantation, personalized chemotherapy guided by drug sensitivity tests, immunotherapy (vaccines, dendritic cells), targeted therapy, and pain management.
Dr. Xiao is a Chief Physician, Professor, and Department Director at Chinese PLA General Hospital. Holding an MD from West China Medical University, Dr. Xiao previously worked at Southwest Hospital. Research focuses on liver and gastrointestinal tumors, supported by multiple National Natural Science Foundation grants. Dr. Xiao has published over 100 papers, holds 11 patents, and received military science progress awards.
Name order: in Chinese the family name comes first (Xiao Wenhua). Papers usually list the name as Wenhua Xiao or Xiao W.
Selected publications
35 papers on PubMed matched by name and affiliation; 12 as first or senior author since 2016. Most recent first- or senior-author papers:
- Medicine (Baltimore), 2026 (senior author): Analysis of a case of immune-related pancreatitis induced by anti-PD-1 antibody therapy for gastric cancer: A case report. PubMed 42854075
- Aging (Albany NY), 2024 (senior author): Revealing prognostic insights of programmed cell death (PCD)-associated genes in advanced non-small cell lung cancer. PubMed 38728242
- Eur J Cancer Prev, 2023 (senior author): A novel prognostic signature contributes to precision treatment in colon adenocarcinoma with KRAS mutation. PubMed 37310401
- Sci Rep, 2023 (senior author): Author Correction: RAB27A promotes the proliferation and invasion of colorectal cancer cells. PubMed 36639433
- Sci Rep, 2022 (senior author): RAB27A promotes the proliferation and invasion of colorectal cancer cells. PubMed 36371494
- Front Cell Dev Biol, 2022 (senior author): Exosomal microRNA panel as a diagnostic biomarker in patients with hepatocellular carcinoma. PubMed 36211468
- Front Oncol, 2022 (senior author): Case Report: Benefits of a NSCLC Patient With EGFR A289G/F287_G288insHA cis Mutations From Immunotherapy in Combination With Antiangiogenesis and Chemotherapy and Sequential Treatment of EGFR-TKI. PubMed 35251994
- Ann Transl Med, 2021 (senior author): Homozygous deletion of the HLA-B gene as an acquired-resistance mechanism to nivolumab in a patient with lung adenocarcinoma: a case report. PubMed 34805368
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion